Skip to content
DraconiticResearch
Search Sources API
209,932 studies31 sourcesUpdated 54 min ago
Peer-reviewedCC BY 4.0Advanced Materials (Deerfield Beach, Fla.)

Advanced Materials for Biologics Delivery to Brain Tumors

  • Yuran Feng1
  • Yuxue Cao2
  • Maria Kavallaris3,4,5
  • Taskeen Janjua1
  • Amirali Popat1
5 affiliations
  1. 1School of Pharmacy and Pharmaceutical Science The University of Queensland Brisbane Queensland Australia
  2. 2Drug Delivery, Disposition and Dynamics Monash Institute of Pharmaceutical Sciences Monash University Melbourne Victoria Australia
  3. 3Children's Cancer Institute at Minderoo Children’s Comprehensive Cancer Centre Sydney New South Wales Australia
  4. 4Australian Centre for NanoMedicine UNSW Sydney Sydney New South Wales Australia
  5. 5School of Clinical Medicine UNSW Medicine & Health UNSW Sydney Sydney New South Wales Australia
Read full textDOICite

Abstract

Brain cancer remains a major global health challenge due to its high morbidity and mortality. Current standard therapies are often limited by incomplete tumor resection, systemic toxicity, and the inability to effectively penetrate the blood‐brain barrier (BBB), which restricts drug delivery to the tumor site. These challenges underscore the urgent need for innovative therapeutic strategies that can overcome these barriers and improve treatment outcomes. Biological materials encompass a diverse range of molecules, from small peptides to monoclonal antibodies, either derived from living organisms or synthetically synthesized. Unlike traditional therapies, biologics provide a more targeted approach, including specific tumor targeting, immune system modulation, and regenerating damaged cells. Although biologics offer significant promise for brain cancer treatment, major challenges associated with blood–brain and tumour barriers continue to limit their translation, and comprehensive reviews bridging therapeutic advances with delivery technologies remain scarce. While individual biologic classes have been extensively studied, a unified assessment of these modalities and their delivery optimization is still needed. This review addresses the current gap by critically examining recent advances in biologic therapies and evaluating emerging invasive and non‐invasive delivery strategies to enhance their therapeutic efficacy in brain cancer.

Related

  1. The future of brain tumor treatment: integrating platelet-based liquid biopsy, advanced drug delivery systems, and eicosanoid inhibition
    Sara Di Berardino, Marta Zarà, Huzaifa Ali Ahfaz +2
    Frontiers in pharmacologyPeer-reviewedCC BYFull textHuman geneticsEurope PMCCrossref
  2. Intranasal delivery of regenerative biologics for neurological disorders: a systematic review of clinical studies
    Umm E Habiba, Iqra Sarwar, Sabiha Shamim +1
    Frontiers in drug deliveryPeer-reviewedCC BYFull textPharmacology & toxicologyEurope PMCPMC
  3. Unexpected Pericardial Cytology in a Patient With Primary Squamous Cell Carcinoma of the Lung: Emphasizing the Need for Advanced Molecular Characterization of Tumors
    Melinda Gevorgian, Alex Minter
    CureusPeer-reviewedCC BYFull textGeneral medicineEurope PMC
  4. Cell-Free Immune-Conditioned Products in Advanced Solid Tumors: A Source-Aware Translational Framework
    Ramón Gutiérrez-Sandoval, Francisco Gutiérrez-Castro, Natalia Muñoz-Godoy +7
    Medicina (Kaunas, Lithuania)Peer-reviewedCC BYFull textGeneral medicineEurope PMC
  5. 548 A phase 1 first-in-human study of ZM008, a novel IgG1 monoclonal antibody targeting LLT1, as monotherapy and combined with toripalimab in patients with advanced solid tumors
    Ignacio Garcia-Ribas, Maloy Ghosh, Sanghamitra Bhattacharjee +6
    Journal for ImmunoTherapy of CancerPeer-reviewedCC BYFull textOncologyDOAJ

Cite

BibTeXRIS
BibTeX
@article{feng2026advanced,
  title = {{Advanced Materials for Biologics Delivery to Brain Tumors}},
  author = {Yuran Feng and Yuxue Cao and Maria Kavallaris and Taskeen Janjua and Amirali Popat},
  journal = {Advanced Materials (Deerfield Beach, Fla.)},
  year = {2026},
  month = aug,
  doi = {10.1002/adma.74760},
  url = {https://doi.org/10.1002/adma.74760},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Advanced Materials for Biologics Delivery to Brain Tumors
AU  - Yuran Feng
AU  - Yuxue Cao
AU  - Maria Kavallaris
AU  - Taskeen Janjua
AU  - Amirali Popat
PY  - 2026
DA  - 2026/08/29
JO  - Advanced Materials (Deerfield Beach, Fla.)
DO  - 10.1002/adma.74760
UR  - https://doi.org/10.1002/adma.74760
AB  - Brain cancer remains a major global health challenge due to its high morbidity and mortality. Current standard therapies are often limited by incomplete tumor resection, systemic toxicity, and the inability to effectively penetrate the blood‐brain barrier (BBB), which restricts drug delivery to the tumor site. These challenges underscore the urgent need for innovative therapeutic strategies that can overcome these barriers and improve treatment outcomes. Biological materials encompass a diverse range of molecules, from small peptides to monoclonal antibodies, either derived from living organisms or synthetically synthesized. Unlike traditional therapies, biologics provide a more targeted approach, including specific tumor targeting, immune system modulation, and regenerating damaged cells. Although biologics offer significant promise for brain cancer treatment, major challenges associated with blood–brain and tumour barriers continue to limit their translation, and comprehensive reviews bridging therapeutic advances with delivery technologies remain scarce. While individual biologic classes have been extensively studied, a unified assessment of these modalities and their delivery optimization is still needed. This review addresses the current gap by critically examining recent advances in biologic therapies and evaluating emerging invasive and non‐invasive delivery strategies to enhance their therapeutic efficacy in brain cancer.
SN  - 0935-9648
SN  - 1521-4095
ER  -